Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model

[1]  Robert N. Anderson,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels , 2013, Journal of the National Cancer Institute.

[2]  S. Garland,et al.  A review of clinical trials of human papillomavirus prophylactic vaccines. , 2012, Vaccine.

[3]  M. Wahiduzzaman,et al.  Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer. , 2012, Vaccine.

[4]  K. Barrios,et al.  TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers , 2012, Cancer Immunology, Immunotherapy.

[5]  D. V. Broeck.  Human Papillomavirus and Related Diseases - From Bench to Bedside - A Clinical Perspective , 2012 .

[6]  K. McKeage,et al.  AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®) , 2011, Drugs.

[7]  J. Webb,et al.  A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. , 2011, Vaccine.

[8]  D. Lowy,et al.  HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. , 2011, Vaccine.

[9]  M. Gómez-Lim,et al.  A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection , 2011, Virology Journal.

[10]  M. Stanley.  HPV - immune response to infection and vaccination , 2010, Infectious Agents and Cancer.

[11]  L. Dillner.  Cutting the research budget , 2010, BMJ : British Medical Journal.

[12]  Cary A Moody,et al.  Human papillomavirus oncoproteins: pathways to transformation , 2010, Nature Reviews Cancer.

[13]  C. Wheeler,et al.  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial , 2010, BMJ : British Medical Journal.

[14]  Xueling Wu,et al.  Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. , 2010, Vaccine.

[15]  S. Hailpern,et al.  Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. , 2009, Viral immunology.

[16]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[17]  F. Casagrande,et al.  Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines , 2009, Journal of Virology.

[18]  M. L. Mora-García,et al.  An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice , 2009, Virology Journal.

[19]  C. Wheeler,et al.  HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. , 2008, Vaccine.

[20]  D. Jenkins.  A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. , 2008, Gynecologic oncology.

[21]  Y. Hirai,et al.  Neutralizing Antibodies against Human Papillomavirus Types 16, 18, 31, 52, and 58 in Serum Samples from Women in Japan with Low-Grade Cervical Intraepithelial Neoplasia , 2008, Clinical and Vaccine Immunology.

[22]  Li Zhao,et al.  Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice , 2008, Molecular Cancer Therapeutics.

[23]  N. Christensen,et al.  Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum , 2007, BMC biotechnology.

[24]  E. Livingston,et al.  Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. , 2007, The Journal of surgical research.

[25]  Martha J. Brown,et al.  Antibodies from Women Immunized with Gardasil ® Cross-Neutralize HPV 45 Pseudovirions , 2007, Human vaccines.

[26]  J. Verbeek,et al.  Uptake of Human Papillomavirus Virus-Like Particles by Dendritic Cells Is Mediated by Fcγ Receptors and Contributes to Acquisition of T Cell Immunity1 , 2007, The Journal of Immunology.

[27]  C. Wheeler,et al.  Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials , 2007, The Lancet.

[28]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[29]  Centro de Investigación,et al.  Transgenic Plants in Therapeutically Valuable Protein Production , 2007 .

[30]  Edson Duarte Moreira Júnior,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.

[31]  T. Huizinga,et al.  Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo. , 2006, Molecular immunology.

[32]  J. Kleinschmidt,et al.  Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly. , 2006, Vaccine.

[33]  D. D. Da Silva,et al.  Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. , 2005, Vaccine.

[34]  L. Willmitzer,et al.  Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic Plants , 2003, Journal of Virology.

[35]  R. Rose,et al.  Oral Immunogenicity of Human Papillomavirus-Like Particles Expressed in Potato , 2003, Journal of Virology.

[36]  D. D. Da Silva,et al.  Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. , 2003, Cancer research.

[37]  I. Frazer,et al.  Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16 , 2003, Immunology and cell biology.

[38]  A. Moscicki,et al.  Time Course of Humoral and Cell-Mediated Immune Responses to Human Papillomavirus Type 16 in Infected Women , 2002, Clinical and Vaccine Immunology.

[39]  P. Coursaget,et al.  Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses , 2002, Journal of Virology.

[40]  R. Angeletti,et al.  Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[42]  P. Coursaget,et al.  Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus‐like particles in colombian women with invasive cervical cancer , 2002, International journal of cancer.

[43]  E. Livingston,et al.  Alternative mRNA splicing in colon cancer causes loss of expression of neural cell adhesion molecule. , 2001, Surgery.

[44]  J. Schiller,et al.  Physical interaction of human papillomavirus virus-like particles with immune cells. , 2001, International immunology.

[45]  A. Kaufmann,et al.  HPV16 L1E7 chimeric virus‐like particles induce specific HLA‐restricted T cells in humans after in vitro vaccination , 2001, International journal of cancer.

[46]  I. Frazer,et al.  Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. , 2000, Virology.

[47]  S. Amigorena,et al.  Fc receptor signaling and trafficking: a connection for antigen processing , 1999, Immunological reviews.

[48]  Sebastian Amigorena,et al.  Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells , 1999, Nature Cell Biology.

[49]  A. Benner,et al.  Immune response to human papillomavirus 16 L1E7 chimeric virus‐like particles: Induction of cytotoxic T cells and specific tumor protection , 1999, International journal of cancer.

[50]  P. Ricciardi-Castagnoli,et al.  Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.

[51]  D. Lowy,et al.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  I. Frazer,et al.  Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. , 1998, Virology.

[53]  D. Galloway,et al.  The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. , 1996, Seminars in cancer biology.

[54]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[55]  D. Lowy,et al.  Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor , 1995, Journal of virology.

[56]  H. Grey,et al.  Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. , 1995, Journal of immunology.

[57]  M. Van Ranst,et al.  Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific. , 1994, The Journal of general virology.

[58]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[59]  D. Lowy,et al.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[60]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[61]  D. W. Weiss,et al.  Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. , 1966, Cancer research.

[62]  D. W. Weiss,et al.  Immunology of Spontaneous Mammary Carcinomas in Mice , 1966 .